Research programme: Rapid Point-of-Care CAR-T cell therapies - EXUMA Biotech

Alternative Names: rPOC CAR-T cell therapies; rPOC SC CAR-T cell therapy

Latest Information Update: 13 Jan 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator EXUMA Biotech
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

11 Jan 2021 EXUMA Biotech and Moffitt Cancer Center agree to co-develop Rapid-Point-Of-Care SC CAR-T Programme for B- cell malignancies
11 Jan 2021 EXUMA Biotech plans a meeting with the US FDA
11 Jan 2021 EXUMA Biotech plans to file an IND application for B-cell malignanices

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com